Although Shewanella algae has been known to have weak pathogenicity, case reports on infections with this species have been steadily increasing. S. algae and S. haliotis are difficult to distinguish from each other with conventional phenotypic methods. We reviewed the microbiological and clinical features of S. algae and S. haliotis infections at our institute. Bacterial culture and identification reports from patient samples from 2010 to 2014 were reviewed to screen the cases of Shewanella infections. In addition to conventional biochemical tests, 16S rRNA gene sequence analysis and matrixassisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry were performed for 19 stored bacterial isolates. Medical records were reviewed for clinical characteristics and laboratory findings. All isolates were identified as S. algae by using VITEK 2. MALDI-TOF also identified all isolates as S. algae with a 99.9 confidence value. In contrast, 16S rRNA analysis identified 10 isolates as S. algae and 9 isolates as S. haliotis. Both S. algae (60z) and S. haliotis (77z) infections were strongly associated with diseases of the hepatobiliary tract and pancreas. To distinguish between S. algae and S. haliotis, 16S rRNA gene sequence analysis seems more accurate than biochemical tests or MALDI-TOF. Patients with underlying diseases in the hepatobiliary tract and pancreas seem to be susceptible to these marine pathogens.
INTRODUCTION
The genus Shewanella comprises gram-negative, nonfermentative, facultative anaerobes, and motile bacilli. Although it is known as an aquatic microorganism, the first Shewanella species (spp.) was isolated from a dairy product (1, 2) . Initially, it was classified as Achromobacter putrefaciens but was renamed as Pseudomonas putrefaciens a decade later. In 1985, it was reclassified into the novel genus Shewanella, according to the phenotypic characteristics of species, namely salt tolerance, growth temperature, and saccharolytic activity (3) . This relatively new genus includes 62 species thus far; however, they are rarely recovered from clinical samples (4) . Case reports of human Shewanella infection are, however, slowly increasing. In the genus Shewanella, particularly 4 species have been reported as human pathogens. S. putrefaciens, S. algae, and S. haliotis were isolated from clinical samples, and S. xiamenensis was recently implicated with human infection (2) . In 1992, S. algae was isolated from red algae and reclassified as a new species that is different from S. putrefaciens in genomic and phenotypic studies (5) . The introduction of S. algae as an infectious pathogen to humans was made much later than that of S. putrefaciens; however, reports about S. algae exceed those of S. putrefaciens. Nevertheless, not all infections suspected to be due to S. algae were found to be caused by this species. In 2007, S. haliotis was first isolated from the gut microflora of abalone. The first case of human infection was reported in Japan, and the second case followed in Thailand (2, 6, 7) . Thus far, the automated identification methods widely used in clinical laboratories cannot completely distinguish S. haliotis from S. algae. Moreover, these 2 Shewanella spp. present similar clinical manifestations, and clear distinctions between them have not been made. We performed 16S rRNA sequencing and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) for the accurate identification of S. algae already recognized with biochemical tests, and also reviewed the clinical characteristics of the species including patient prognosis.
MATERIALS AND METHODS
Electronic medical records from January 2010 to December 2014 were reviewed to screen Shewanella infections for all bacterial culture and identification results from Gyeongsang National University Hospital. Biochemical identification and antibiotic susceptibility tests were performed by using a VITEK 2 system (bioMerieux Inc., Marcy l'Etoile, France) for frozen stored isolates reported as S. algae. Because Khashe et al. (8) reported that biochemical and enzymatic properties of S. algae were variable according to the incubation time, we limited the incubation time up to 18 h.
As the Clinical and Laboratory Standards Institute (CLSI) has not provided the minimal inhibitory concentration (MIC) interpretative standards for Shewanella spp., we applied CLSI-approved standard M100-S22 (9) . As only 2 Shewanella spp., S. putrefaciens and S. algae, were registered in the database of the VITEK 2 system, additional identification by using 16S rRNA gene sequence analysis (Macrogen, Seoul, Korea) and MALDI-TOF MS (bioM áerieux Inc.) with the database V2 released in November 2012 were performed. Electronic medical records were reviewed for demographics, underlying diseases, clinical courses, and laboratory results. The statistical significance of laboratory tests was examined by using the Wilcoxon signed-rank test. All statistical analyses were performed with SPSS, version 21 (IBM Corp., Armonk, NY, USA), and statistical significance was defined when the p value was ＜0.05. This protocol was reviewed by an institutional review board.
RESULTS
Thirty patients were identified as having S. algae infections through medical record reviews. We analyzed only 19 patients whose isolates were stored in the Gyeongnam regional center of the National Culture Collection for Pathogens. The VITEK 2 system identified the strains as S. algae with 99z probability. In addition, MALDI-TOF MS made the same conclusion with a 99.9 confidence value. Interestingly, 16S rRNA gene sequencing identified 9 isolates as S. haliotis. Even in 16s rRNA sequencing, these 2 species had only 10-odd different base pairs. On the basis of 16s rRNA gene sequencing, we divided the strains into 2 species: S. algae and S. haliotis. Table 1 shows the clinical characteristics of the 2 Shewanella spp. S. haliotis infections showed a male predilection (male-to-female ratio 7:2), whereas S. algae did not. The mean ages were similar: 66.7 years for S. algae and 63.2 years for S. haliotis. The proportion of underlying diseases of the hepatobiliary tract and pancreas including malignancy was 60z (6 of 10) for the S. algae group and 78z (7 of 9) for the S. haliotis group. The current diagnoses associated with S. algae (n ＝ 10) consisted of 50z cholecystitis and/or cholangitis with or without stones, 30z lower gastrointestinal tract problems, and 10z septic shock. One patient without underlying comorbidities was admitted for a traumatic hemopneumothorax sustained while on a fishing boat. The current diagnoses associated with S. haliotis (n ＝ 9) showed similar patterns and consisted of 55z cholecystitis and/or cholangitis, 22z lower gastrointestinal tract problems, and 11z cellulitis. A healthy patient who complained of blurred vision was diagnosed as having keratitis due to S. haliotis. The presence of percutaneous transhepatic biliary drainage (PTBD) or percutaneous transhepatic gallbladder drainage (PTGBD) was also remarkable both in patients with S. algae (50z) and S. haliotis (44z). The collected samples mostly comprised bile juice drained with PTBD or PTGBD (n ＝ 7), followed by blood (n ＝ 5), wound pus (n ＝ 5), ascites (n ＝ 4), and eye swab (n ＝ 1). The clinical courses ranged from mild to severe, and even fatal. The most severe clinical course resembled that of Vibrio vulnificus infection. The patient died of rapidly aggravated septic shock and necrotizing fasciitis caused by S. algae. In fact, this case was initially thought to be V. vulnificus infection. The other patients infected with either S. algae or S. haliotis survived within 21 days of isolation. The mean isolation period was 12.8 ± 16.6 days for S. algae and 6.3 ± 10.11 days for S. haliotis after admission.
Although we compared key laboratory findings, there were no significant differences between the 2 groups (p ＞ 0.05). Leukocytosis was observed in 50z and 55z of patients with S. algae and S. haliotis infection, respectively. Increase of C-reactive protein was The number in the parenthesis shows a percentage. 
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Shewanella haliotis and Shewanella algae observed in all patients except one. In liver function tests, alkaline phosphatase, aspartate aminotransferase, and alanine aminotransferase levels increased moderately.
Among the results of 41 biochemical tests with VITEK II, no specific differences were clarified to distinguish between the 2 species. Table 2 demonstrates any discordant test results between these 2 species.
In Table 3 , both S. algae and S. haliotis showed high susceptibility rates against the tested antibiotics except imipenem (50z and 44z, respectively).
The occurrence of S. algae infections was more prominent in summer and autumn when the mean temperature of the ocean surface was ＞209 C (Fig. 1) . In contrast, S. haliotis infections were steadily observed regardless of the ocean surface temperature.
DISCUSSION
The genus Shewanella inhabits aquatic environments, usually seawater. S. algae was separately identified from S. putrefaciens in 1992 (5). Since S. algae was added to the database of commercial identification systems a decade ago, this species has been easily differentiated from S. putrefaciens. S. algae causes a wide range of infections, including otitis media, cholecystitis, cholangitis, liver abscess, bacteremia, nonhealing ulcer, gastroenteritis, osteomyelitis, cellulitis, pneumonia, peritonitis, and septicemia, similar to V. vulnificus (9) (10) (11) (12) (13) (14) . In 2007, S. haliotis was first isolated from the gut microflora of abalone by Kim et al. (6) . This species was also shown to be a causal agent of human infections (2, 6) .
Although these species were related to marine environments, only 3 patients had a clear documented history of exposure to seawater or consumption of raw or undercooked seafood. As these bacteria are not well known human pathogens, the physicians might have paid little attention to these species and did not perform careful history taking. However, we can only suggest that the facts that our institute is located in a rural area near the ocean, and that the residents of this region more frequently consume raw seafood and are exposed to seawater than people in urban areas, may play some role.
We found a strong association between Shewanella infection and hepatobiliary tract diseases (both inflammation and malignancy). More than half of the patients had underlying diseases in the hepatobiliary tract and pancreas. The patients had structural changes caused by cholangiocarcinoma, including intrahepatic site or Klatskin tumor or pancreatic cancer. Biliary stones, which may induce cholestasis, were also prevalent in our patients. The lipophilicity and tolerance to bile salts of Shewanella spp. make the hepatobiliary tract a niche for S. algae and S. haliotis (10) . The presence of external drainage catheters in the hepatobiliary system and the existence of hepatobiliary diseases were the most important risk factors in a previous matched case-control study (15) . In our study, S. algae and S. haliotis had indwelling PTBD or PTGBD in 50z and 44z of cases, respectively. Because S. algae and S. haliotis usually do not inhabit human skin, external drainage itself does not play a role as an entrance for bacteria. Nevertheless, anatomical anomalies of the hepatobiliary tract are conditions necessitating external drainage, and carry the risk of the development of infection.
Liu et al. (9) reported on patients who showed Shewanella infection as a primary manifestation and were then diagnosed as having hepatobiliary malignancy. Therefore, it would be beneficial for patients if hidden malignancies are detected. In contrast to the previous study, no patients were newly diagnosed with a malignancy in our study.
An outbreak of Shewanella infection in a Korean tertiary hospital provided another route for invasion in humans, where a shared measuring cup was the source of hospital-associated infection through contact transmission. The estimated incubation period was reported to be 3-49 days (15) . The incubation period of our cases ranged from 1 to 51 days, and 78.9z (15 of 19) were isolated ＜2 weeks from the admission date. From our data analysis, nosocomial infection was not a possible route for our patient groups.
One S. haliotis and 2 S. algae infection cases had resistance against imipenem. The 2 patients with imipenem-resistant S. algae strain had no history of exposure to carbapenem. One patient had received second-generation cephalosporin, and the other received third-generation cephalosporin, ampicillin/sulbactam, and metronidazole for co-isolates other than S. algae. Although they were not exposed to carbapenem, the isolates had resistance against imipenem. In contrast, meropenem had been administered to the patient with imipenem-resistant S. haliotis as this patient was previously infected with extended-spectrum beta-lactamase positive Escherichia coli. After the medical treatment, all patients recovered and no further Shewanella spp. was isolated from follow-up cultures. Figure 1 shows that S. haliotis infections occurred regardless of the ocean surface temperature, whereas S. algae infections peaked in summer and autumn when the ocean surface temperature was ＞209 C. This may be due to the greater tolerance to cold temperature of S. haliotis. Previous studies mentioned the mesophilic features of S. algae (10, 16) . Because the 2 Shewanella spp. of our interest were not separated in those studies, the temperature peculiarity of each species should be examined.
This study included only 19 patients at a single institute. To make a more representative comparison of S. algae and S. haliotis, more strains from a nationwide sample would be required.
We found that some strains identified as S. algae with biochemical methods were in fact S. haliotis in 16S rDNA sequence analysis. The newly adopted MALDI-TOF could not differentiate between the 2 species. Moreover, the clinical manifestations, laboratory findings, and antibiotic susceptibility tests of the 2 species were not largely different from each other. For these reasons, it is difficult to differentiate them without molecular methods. Although Shewanella infections have shown good prognosis, these emerging human pathogens that can cause infections especially in patients with underlying hepatobiliary comorbidities should be watched closely.
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